RecruitingPhase 4NCT07410988

Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications

Effect of 130/0.4 Hydroxyethyl Starch vs. Balanced Crystalloid for Intraoperative Fluid Therapy on Major Composite Renal Outcomes After Cardiac Surgery: a Multicenter, Randomized Controlled Trial

Sponsor

Seoul National University Hospital

Enrollment

1,292 participants

Start Date

Jun 22, 2026

Study Type

INTERVENTIONAL

Conditions

Cardiac Surgery

Summary

This trial aims to compare two intraoperative fluids, namely hydroxyethyl starch (HES) and balanced crystalloids in terms of major adverse kidney events after cardiac surgery. Indications for the study fluids administarion include preload augmentation and intravascular volume replacement during cardiac surgery.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Crystalloid solutions and a drug called Volulyte® (6% HES 130/0.4 in balanced solution) for people with cardiac surgery. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVolulyte® (6% HES 130/0.4 in balanced solution)

Hydroxyethyl starch is used (up to 20 mL/kg) when acute volume resuscitation is required (e.g., preload augmentation, intravascular volume replacement) during cardiac surgery.

DRUGCrystalloid solutions

Balanced crystalloids are used instead of HES for the same indications as those in the HES group (when acute volume resuscitation is required \[e.g., preload augmentation, intravascular volume replacement\] during cardiac surgery).